|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for ARHGAP35 |
 Gene summary |
| Basic gene Info. | Gene symbol | ARHGAP35 |
| Gene name | Rho GTPase activating protein 35 | |
| Synonyms | GRF-1|GRLF1|P190-A|P190A|p190ARhoGAP|p190RhoGAP | |
| Cytomap | UCSC genome browser: 19q13.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_004491.4, NM_024342.1, | |
| Description | glucocorticoid receptor DNA binding factor 1glucocorticoid receptor DNA-binding factor 1glucocorticoid receptor repression factor 1rho GAP p190Arho GTPase-activating protein 35 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 605277 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000160007 | ||
| HPRD : 05592 | ||
| Vega : OTTHUMG00000183438 | ||
| Protein | UniProt: Q9NRY4 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_ARHGAP35 | |
| BioGPS: 2909 | ||
| Pathway | NCI Pathway Interaction Database: ARHGAP35 | |
| KEGG: ARHGAP35 | ||
| REACTOME: ARHGAP35 | ||
| Pathway Commons: ARHGAP35 | ||
| Context | iHOP: ARHGAP35 | |
| ligand binding site mutation search in PubMed: ARHGAP35 | ||
| UCL Cancer Institute: ARHGAP35 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0000122 | negative regulation of transcription from RNA polymerase II promoter | 1894621 | GO:0045892 | negative regulation of transcription, DNA-templated | 1894621 |
| Top |
| Ligand binding site mutations for ARHGAP35 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | A230 | A230V | COAD | 1 | R231 | S232Y | LUSC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for ARHGAP35 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | A230 | A230V | -0.42772625 | R231 | S232Y | -0.154653 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for ARHGAP35 from PDB |
| Top |
| Differential gene expression and gene-gene network for ARHGAP35 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for ARHGAP35 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for ARHGAP35 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of ARHGAP35 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | GNP | PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER | 3c5h | A | A230 R231 |
| Top |
| Conservation information for LBS of ARHGAP35 |
| Multiple alignments for Q9NRY4 in multiple species |
| LBS | AA sequence | # species | Species | A230 | VVETSARSNVN | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | C37 | GIGKSCLCNRF | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | D203 | VLTKCDEGVER | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | E95 | KMHIVEQTEFI | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | G32 | EKGQCGIGKSC | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | G34 | GQCGIGKSCLC | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | I33 | KGQCGIGKSCL | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | K201 | VVVLTKCDEGV | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | K28 | GTEKEKGQCGI | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | K35 | QCGIGKSCLCN | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | L52 | ADEFHLDHTSV | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | R231 | VETSARSNVNV | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | S229 | QVVETSARSNV | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | S36 | CGIGKSCLCNR | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | S56 | HLDHTSVLSTS | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris | T97 | HIVEQTEFIDD | 3 | Homo sapiens, Mus musculus, Canis lupus familiaris |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |